Top

Published in:

01-08-2007 | Original

Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent

Authors: Gloria García-Segarra, Gerard Espinosa, Dolors Tassies, Josep Oriola, Jesús Aibar, Albert Bové, Pedro Castro, Joan-Carles Reverter, Josep-Maria Nicolás

Published in: Intensive Care Medicine | Issue 8/2007

Abstract

Objective

To evaluate the effect of the 4G/5G PAI-1 gene polymorphism on the development of organ failure and outcome in critically ill patients with septic syndromes.

Design and setting

Prospective, observational study in a medical intensive care unit of a university hospital.

Patients

224 consecutively admitted patients.

Interventions

Epidemiological data, severity scores, and the primary site of infection were recorded. DNA genotyping of the PAI-1, TNF-β, and IL1-ra genes, and measurement of plasma PAI-1 antigen and D-dimer were carried out.

Measurements

The primary outcome variables were organ dysfunction and mortality.

Results

Eighty-eight subjects had septic shock at ICU entry or within 48 h from admission. Homozygotes for the 4G allele exhibited higher plasma concentrations of PAI-1 antigen and D-dimer than 4G/5G and 5G/5G subjects). ICU mortality was 44.0% in patients with 4G/4G, 23.4% in 4G/5G and 12.5% in 5G/5G, mainly due to multiorgan failure. After adjusting for SAPS II at admission the genotypes independently associated with ICU mortality in septic shock were TNF-B2/B2 (OR 2.83, 1.04–7.67) and 4G/4G of PAI-1 (OR 2.23, 1.02–4.85). The PAI-1 genotype did not determine susceptibility to infection or the outcome in nonseptic systemic inflammatory response syndrome, sepsis, severe sepsis, and nosocomial septic shock.

Conclusions

Homozygosity for 4G of the PAI-1 gene confers an increase in the risk of mortality in adult patients with septic shock due to a greater organ failure.

Available only for authorised users

Angus D, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310PubMedCrossRef

Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554PubMedCrossRef

Nadel S, Newport MJ, Boody Booy R, Levin M (1996) Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 174:878–880PubMed

Waterer GW, Quasney MW, Cantor RM, Wunderink RG (2001) Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 163:1599–1604PubMed

Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut JF (1999) Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 282:561–568PubMedCrossRef

Majetschak M, Flohe S, Obertacke U, Schroder J, Staubach K, Nast-Kolb D, Schade FU, Stuber F (1999) Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 230:207–214PubMedCrossRef

Fang XM, Schroder S, Hoeft A, Stuber F (1999) Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 27:1330–1334PubMedCrossRef

Dellinger RP (2003) Inflammation and coagulation: implications for the septic patient. Clin Infect Dis 36:1259–1265PubMedCrossRef

Kornelisse RF, Hazelzet JA, Savelkoul HFJ, Hop WC, Suur MH, Borsboom AN, Risseeuw-Appel IM, van der Voort E, de Groot R (1996) The relationship between plasminogen activator inhibitor-1 and proinflammatory and counter-inflammatory mediators in children with meningoccocal septic shock. J Infect Dis 173:1148–1156PubMed

10.

Vervloet MG, Thijs LG, Hack CE (1998) Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 24:33–44PubMedCrossRef

11.

Mesters RM, Florke N, Ostermann H, Kienast J (1996) Increase of plasminogen activator inhibitor levels predicts outcome of leukopenic patients with sepsis. Thromb Haemost 75:902–907PubMed

12.

Ryan MP, Kutz SM, Higgins PJ (1996) Complex regulation of plasminogen activator inhibitor type-1 (PAI-1) gene expression by serum and substrate adhesion. Biochem J 314:1041–1046PubMed

13.

Horrevoets JG (2004) Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance. Br J Haematol 125:12–23PubMedCrossRef

14.

Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268:10739–10745PubMed

15.

Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M (1999) 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 354:556–560PubMedCrossRef

16.

Westendorp RG, Hottenga JJ, Slagboom PE (1999) Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 354:561–563PubMedCrossRef

17.

Haralambous E, Hibberd ML, Hermans PW, Ninis N, Nadel S, Levin M (2003) Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 31:2788–2793PubMedCrossRef

18.

Menges T, Hermans PW, Little SG, Langefeld T, Boning O, Engel J, Sluijter M, de Groot R, Hempelmann G (2001) Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 357:1096–1097PubMedCrossRef

19.

Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66:155 cases and 91:307 controls. Lancet 367:651–658PubMedCrossRef

20.

Sirgo G, Perez-Vela JL, Morales P, Del Rey M, Vendrell J, Gutierrez C, Rello J (2006) Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy alter cardiac surgery. Intensive Care Med 32:668–675PubMedCrossRef

21.

Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K (2005) Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 36:1661–1665PubMedCrossRef

22.

Castello R, Espana F, Vazquez C, Fuster C, Almenar SM, Aznar J, Estelles A (2006) Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res 117:487–492PubMedCrossRef

23.

Hizawa N, Maeda Y, Konno S, Fukui Y, Takahashi D, Nishimura M (2006) Genetic polymorphisms at FCER1B and PAI-1 and asthma susceptibility. Clin Exp Allergy 36:872–876PubMedCrossRef

24.

Glueck CJ, Sieve L, Zhu B, Wang P (2006) Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 55:345–352PubMedCrossRef

25.

Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections. Am J Infect Control 16:128–140PubMedCrossRef

26.

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, for the International Sepsis Definitions Conference (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250–1256PubMedCrossRef

27.

Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R (1994) The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824PubMed

28.

Murray JF, Matthay MA, Luce JM, Flick MR (1988) An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 139:720–723

29.

Reber G, Bounameaux H, Perrier A, de Moerloose P (2001) Performances of a new, automated latex assay for the exclusion of venous thromboembolism. Blood Coagul Fibrinolysis 12:217–220PubMedCrossRef

30.

Declerck PJ (1988) Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immuno-sorbant assay. Blood 71:220–225PubMed

31.

Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, d'Addedda M, Di Minno G (1997) An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 77:605–606PubMed

32.

Schaaf BM, Seitzer U, Pravica V, Aries SP, Zabel P (2001) Tumor Necrosis Factor-a-308 promoter gene polymorphism and increased tumor necrosis factor serum bioactivity in farmer's lung patients. Am J Respir Crit Care Med 163:379–382PubMed

33.

Tarlow JK, Blakemore AIF, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW (1993) Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable number of an 86-bp tandem repeat. Hum Genet 91:403–404PubMedCrossRef

34.

Stuber F, Petersen M, Bokelmann F, Schade U (1996) A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24:381–384PubMedCrossRef

35.

Dempfle CE (2004) Coagulopathy in sepsis. Thromb Haemost 91:213–224PubMed

36.

Levi M, Ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341:586–592PubMedCrossRef

37.

Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR (2005) Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 33:341–348PubMedCrossRef

38.

Mavrommatis AC, Theodoridis T, Economou M, Kotanidou A, El Ali M, Christopoulou-Kokkinou V, Zakynthinos SG (2001) Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med 27:1853–1859PubMedCrossRef

39.

Okabayashi K, Wada H, Ohta S, Shiku H, Nobori T, Maruyama K (2004) Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol 76:225–229PubMedCrossRef

40.

Hoekstra T, Geleijnse JM, Schouten EG, Kluft C (2002) Diurnal variation in PAI-1 activity predominantly confined to the 4G-allele of the PAI-1 gene. Thromb Haemost 88:794–798PubMed

41.

Hattersley AT, McCarthy MI (2005) What makes a good genetic association study? Lancet 366:1315–1323PubMedCrossRef

42.

Boekholdt SM, Bjisterveld NR, Moons AH, Levi M, Buller HR, Peters RJ (2001) Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 104:3063–3068PubMed

43.

Ding J, Nicklas BJ, Fallin MD, de Rekeneire N, Kritchevsky SB, Pahor M, Rodondi N, Li R, Zmuda JM, Harris TB (2006) Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 152:1109–1115PubMedCrossRef

44.

Goor ML van, Gomez Garcia E, Leebeek F, Brouwers GJ, Koudstaal P (2005) The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. Thromb Haemost 93:92–96

45.

Lazo-Langner A, Knoll GA, Wells PS, Carson N, Rodger A (2006) The risk of dyalisis access thrombosis is related to the transforming growth factor-beta1 production haploptype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene. Blood 108:4052–4058PubMedCrossRef

46.

Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH (2006) The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thromb Haemost 96:471–477PubMed

47.

Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM (2006) Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type-2 diabetes. Circulation 113:1753–1759PubMedCrossRef

48.

Speleman L, Kerrebin JD, Look MP, Meeuwis CA, Foekens JA, Berns EM (2006) Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Head Neck 29:341–350CrossRef

49.

Offersen BV, Pfeiffer P, Andreassen P, Overgaard J (2007) Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer 56:43–50PubMedCrossRef

50.

Holmes CL, Russell JA, Walley KR (2003) Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 124:1103–1115PubMedCrossRef

Title: Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent
Authors: Gloria García-Segarra
Gerard Espinosa
Dolors Tassies
Josep Oriola
Jesús Aibar
Albert Bové
Pedro Castro
Joan-Carles Reverter
Josep-Maria Nicolás
Publication date: 01-08-2007
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 8/2007
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-007-0695-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent

Abstract

Objective

Design and setting

Patients

Interventions

Measurements

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Design and setting

Patients

Interventions

Measurements

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2007

High-mobility group box 1 protein plasma concentrations during septic shock

Understanding high-frequency oscillation: lessons from the animal kingdom

Comment on “Incidence, risk factors and consequences of ICU delirium” by Ouimet et al.

End-inspiratory occlusion maneuver during transesophageal echocardiography for patent foramen ovale detection in intensive care unit patients

A postural change test improves the prediction of a radiological maxillary sinusitis by ultrasonography in mechanically ventilated patients

ICUs: from performance appraisal to executive dashboard?